Acer Therapeutic

ACER NASDAQ
3.260
-0.140
-4.12%
Opening 14:36 07/15 EDT
Open
3.430
Prev Close
3.400
High
3.430
Low
3.190
Volume
150.70K
Avg Vol (3M)
286.61K
52 Week High
34.10
52 Week Low
3.190
% Turnover
1.49%
Market Cap
32.88M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Acer Therapeutic ACER stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
MORE >

Recently

Name
Price
%Change